WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer

SHANGHAI and AUSTIN, Texas, April 8, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.


In this executive role, Dr. Hausheer will provide medical, scientific and operational leadership to WuXi Clinical operations in the United States, China and other territories. In addition, he will play a key role in forging and maintaining strong connections between our customers and WuXi's business units by providing inputs on medical and clinical development strategies aimed at seamless integration from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV clinical development plans for our customers.


Dr. Hausheer brings more than 30 years' experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings. He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.


"We're very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer," said Mr. Edward Hu, Co-CEO of WuXi AppTec. "Dr. Hausheer's rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen WuXi's clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world."


Prior to joining WuXi, Dr. Hausheer held CEO and CMO positions with several Biopharma companies, and was the Founder and Chairman of BioNumerik Pharmaceuticals. He has also served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. Early in his career he served on the National Cancer Institute (NCI) Experimental Therapeutics Section, the NCI Decision Network Panel, and the NCI Institutional Review Board, followed by extensive involvement in national and international Phase I-III clinical trials involving novel treatments for lung, breast, ovarian and other malignancies.


Dr. Hausheer obtained his MD at the University of Missouri, School of Medicine and then became a faculty member at the Johns Hopkins Oncology Center, where he focused on the development of novel experimental therapeutics and pharmacology. He currently holds adjunct professorships at the University of Missouri in Internal Medicine and Oncology and The Johns Hopkins Oncology Center in Medical Oncology. He is an inventor/co-inventor on more than 400 issued United States and international patents.


About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com


Cision View original content:http://www.prnewswire.com/news-releases/wuxi-apptec-appoints-dr-frederick-h-hausheer-as-chief-medical-officer-300825787.html

Related Links :

http://www.wuxiapptec.com

Tags:
Look out for further updates on our Facebook fan page!

Related Articles

  • 【人才管理】欣賞員工唔一定要用錢嘅! 專家建議5個方法一樣得

    疫情下老闆當然撐得辛苦,但員工也正在拼命為公司付出。一間企業成功與否,除了在於老闆的領導能力和視野,留住人才也是一大關鍵......

  • 【人才管理】真金助員工渡難關!Facebook宣布向員工派發獎金$7700元

    新冠肺炎擴散全球,各國的經濟受到不同程度的打擊。企業面減虧蝕、停業甚至倒閉風險,打工仔則面臨減薪、失業的壓力。根據美國有線電視新聞網(CNN) 報導,科技巨頭Facebook宣布向4萬5千名員工發放1,000美元的補助金(約7,766港元)。

  • 【企業管理】流動網絡普及 企業貪快貪方便蒙受損失

    【經濟日報專訊】流動網絡普及,人人一機在手即可在網上四通八達。可是,這亦令流動安全防護變得複雜,讓黑客及不法分子有機可乘。

  • 【新冠肺炎】員工怕「中招」拒上班 管理層無法說服結果......

    疫情嚴重影響到各大企業的運作,如果業務性質許可,企業能安排員工在家工作(Work From Home)當然最好,但是部分行業難以實行......

  • 【新冠肺炎】公務員逐步復工 專家︰企業是否跟隨考慮幾個因素

    【經濟日報專訊】本港由上月23日出現首宗新冠肺炎(武漢肺炎)輸入個案,至昨累計達93宗,接近破百關口,而昨2宗確診個案,均涉北角佛堂群組。而下周就踏入3月,本港疫情是否有回落迹象?社會是否應恢復正常工作安排?

  • 【新冠肺炎】確診新冠肺炎前有症狀仍上班 網民:社畜病毒威力太強大

    截至今早10時半,最新香港新冠肺炎(武漢肺炎)的確診個案已上升至68宗,2人死亡,仍有111宗個案仍需住院檢查。雖然鑑於疫情嚴......

  • 【網民職場Talk】下屬奉旨幫上司執手尾?打工仔列慘痛經歷

    打工仔工作繁忙,加上工時長,每天與同事相處的時間比家人、伴侶、朋友還要多,如果不幸遇上能力不高的上司,更會為工作添煩添亂。一個體貼下屬、表現出眾的上司,可謂可遇不可求,當你在職場打滾多年後,或許會發現職位高低往往與能力的高低不成正比。有網民向社交媒體專頁《奴工處》投稿,分享為人下屬的辛酸。

  • 【職場熱話】18區最痛苦的返工地點!觀塘熱到變蒸爐?

    香港的打工仔的確可憐,朝朝起身迫巴士、港鐵上班,人多車又疏,最弊近幾日天氣熱到令人中暑,未回到公司已經大汗疊細汗,成身臭味。一早起身壓力已經爆煲,有網友忍不住要在討論區開Post,讓大家一起「嚴選最地獄返工地點」,不知道哪區是你的心水呢?

  • 【網民職場Talk】大學Third Hon畢業 連累失面試機會?

    大學生近日陸續完成課程,開始踏上求職之路。若在大學取得一級榮譽(First Hon),可能會為CV加分,但在取得三級榮譽(Third Hon)的話,又會否影響僱主聘請意欲呢?有Third Hon畢業生遲遲未找到工作,在社交專頁《奴工處》投稿,了解Third Hon是否真的影響求職。

  • 【政府工略】政府統計處請統計助理 月薪$20,035 點先做到?

    政府統計處最近招聘統計助理,只要你持有香港統計學會頒發的統計學普通證書,或者擁有以下學歷即可申請,月薪$20,035,以非公務員合約條款受聘,為期約6月12個月。